Results 31 to 40 of about 13,643,061 (311)

Optimal D-STATCOM Placement Tool for Low Voltage Grids

open access: yesEnergies, 2021
In low-voltage grids with a wide spread of domestic and/or small commercial consumers, mostly single-phase, problems can appear due to unbalanced power consumption between the different phases.
Gregorio Fernández   +9 more
doaj   +1 more source

Elfving's Theorem for $D$-Optimality

open access: yesThe Annals of Statistics, 1993
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
openaire   +2 more sources

The Re-Modeling of a Polymeric Drug Delivery System Using Smart Response Surface Designs: A Sustainable Approach for the Consumption of Fewer Resources

open access: yesChemEngineering
Introduction: The use of response surface designs for drug formulation is highly warranted nowadays. Such smart designs reduce the number of required experiments compared to full-factorial designs, while providing highly accurate and reliable results ...
Magdy M. Aly   +2 more
doaj   +1 more source

Complex D-optimal designs

open access: yesDiscrete Mathematics, 1996
Let \(g(n)\) (resp. \(\gamma(n)\)) be the maximum absolute value of the determinant of all \(n\times n\) matrices whose entries are from \(\{1,-1\}\) (resp. \(\{1,-1,i,-i\})\). The following theorems are proved: (1) \(g(2m)\geq 2^m(\gamma(m))^2\), with equality iff there exists a matrix of the form \((\begin{smallmatrix} A & B\\ -B & A\end{smallmatrix})
openaire   +2 more sources

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman   +7 more
wiley   +1 more source

A D-optimal design of order 102

open access: yesDiscrete Mathematics, 1992
The author describes a computer search to construct a \(D\)-optimal design of order 102.
openaire   +2 more sources

A D-optimal design of order 150

open access: yesDiscrete Mathematics, 1998
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
Wolf H. Holzmann, Hadi Kharaghani
openaire   +2 more sources

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta   +6 more
wiley   +1 more source

The Nonequivalent Circulant D-Optimal Designs for n=2 mod 4, n<=54, n=66

open access: yes, 1994
All non-equivalent circulant D-optimal designs for n ≡ 2 mod 4, n ⩽ 54 and n = 66 are given and were found by an exhaustive search. There is a unique non-equivalent circulant design for each value of n ⩽ 18, 3 for n = 26 and n = 30, 8 for n = 38, 31 for ...
Nikolaou, N   +3 more
core   +1 more source

The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear.
Laila Alkhouli   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy